Acta Oncologica (May 2024)

The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST

  • Loic Verlingue,
  • Marine Desevre,
  • Marie Polito,
  • Gwenaelle Garin,
  • Christine Rodriguez,
  • Wang Qing,
  • Olivier Tredan,
  • David Perol,
  • Isabelle Ray-Coquard,
  • Sylvie Chabaud,
  • Jean Yves Blay

DOI
https://doi.org/10.2340/1651-226X.2024.32745
Journal volume & issue
Vol. 63, no. 1

Abstract

Read online

Background and purpose: In this manuscript we describe the academic French multicentric molecular analysis platforms including PROFILER, promoted by Centre Léon Berard, and the multicentric personalized medicine trials MOST, MOST Plus and MEGAMOST. Patients/material and methods: MOST, MOST Plus and MEGAMOST comprise 14 cohorts with different targeted agents and immunotherapies. Results and interpretation: PROFILER has recruited 5,991 patients in 10 years, MOST and MOST Plus 875 patients since 2014 and MEGAMOST 172 patients since 2020, and are still ongoing. We provide a description of the local, national and international implications of these initiatives, and we review the results of the sorafenib and olaparib cohorts.

Keywords